In patients with age‑related macular degeneration, does light therapy prevent disease progression and maintain baseline visual function?

Light Therapy for Macular Degeneration: Does Not Prevent Progression or Maintain Baseline

Light therapy (photobiomodulation) is not recommended for preventing AMD progression or maintaining baseline visual function, as it lacks support from major ophthalmology guidelines and shows inconsistent evidence from clinical trials. The established interventions for slowing AMD progression remain AREDS2 supplementation, smoking cessation, and anti-VEGF therapy for neovascular disease.

Guideline-Based Standard of Care

The American Academy of Ophthalmology's comprehensive guidelines for AMD management make no mention of light therapy as a recommended intervention 1, 2. The evidence-based interventions that actually prevent progression include:

• AREDS2 supplementation (vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin) reduces progression to advanced AMD by approximately 25% in high-risk patients with intermediate AMD or advanced disease in one eye 1, 3
• Smoking cessation is mandatory, as smoking increases AMD progression risk in a dose-dependent manner based on pack-years 1, 3
• Anti-VEGF therapy (ranibizumab, aflibercept, bevacizumab, brolucizumab) for neovascular AMD, initiated immediately upon diagnosis, reduces legal blindness and visual impairment 1, 2

Light Therapy Evidence: Mixed and Insufficient

The research on photobiomodulation shows conflicting results that do not support routine clinical use:

Potentially Positive Studies (But Limited)

• The LIGHTSITE III trial (2024) showed a modest 2.4-letter difference favoring multiwavelength PBM over sham at 13 months, though both groups improved (PBM: 5.4 letters, Sham: 3.0 letters) 4
• A 2024 Italian study using the EYE-LIGHT device showed 20.3% of treated patients gained ≥5 letters versus 8.9% in sham group at 4 months, but this is short-term data only 5
• LIGHTSITE I (2020) showed 4-letter gains immediately after treatment, with approximately 50% of PBM-treated subjects improving ≥5 letters versus 13.6% sham-treated at Month 1, but benefits required repeated treatments to maintain 6

Negative or Concerning Studies

• A 2018 randomized controlled trial of nighttime light therapy (505 nm) showed no substantial effect on AMD progression over 12 months (38.1% progression in intervention group vs 48.3% in controls, not statistically significant) 7
• Critically, this same study found an adverse effect: light therapy caused a significantly larger delay in cone dark adaptation (1.66 minutes) compared to controls (0.66 minutes), raising safety concerns 7
• A 2020 pilot study of 670 nm red light in 31 patients with intermediate AMD showed no significant improvement in any functional or structural parameters at any time point up to 12 months 8

Why Light Therapy Is Not Standard Practice

The fundamental problem: Light therapy has not been incorporated into any major ophthalmology practice guidelines despite years of investigation 1, 2. The U.S. Preventive Services Task Force recommendations for AMD screening and treatment similarly make no mention of light therapy 9.

Key Limitations:

• Inconsistent efficacy: Studies show variable results ranging from modest benefits to no effect 4, 5, 6, 7, 8
• Short-term data: Most positive studies have follow-up of only 4-13 months, insufficient to demonstrate disease modification in a chronic progressive condition 4, 5, 6
• Lack of durability: Benefits appear to require repeated treatment series to maintain, suggesting symptomatic rather than disease-modifying effects 6, 10
• Potential harm: At least one well-designed RCT demonstrated adverse effects on dark adaptation 7
• No FDA approval: No photobiomodulation device has received FDA approval for AMD treatment or prevention

What Actually Works: Evidence-Based Algorithm

For patients with early or intermediate AMD:

1. Prescribe AREDS2 supplementation for all patients with intermediate AMD (bilateral large drusen ≥125 μm) or advanced AMD in one eye—this prevents progression in approximately 25% and could benefit over 300,000 Americans if universally adopted 1, 3

2. Mandate smoking cessation with counseling—smoking is the most consistently identified modifiable risk factor, with risk proportional to pack-years 1, 3

3. Optimize lifestyle factors: Maintain healthy BMI, increase dietary intake of green leafy vegetables and fish rich in omega-3 fatty acids—these interventions can prevent 56-60% of incident advanced AMD even in genetically high-risk populations 11

4. Schedule regular comprehensive eye examinations because early AMD is asymptomatic, and timely detection enables intervention when most beneficial 1, 3

5. For neovascular AMD: Initiate anti-VEGF therapy immediately upon diagnosis using aflibercept, ranibizumab, bevacizumab, brolucizumab, or faricimab—this is the only proven treatment to reduce legal blindness in wet AMD 1, 2, 12

Clinical Bottom Line

Do not recommend light therapy for AMD progression prevention. Instead, focus on the proven triad of AREDS2 supplementation, smoking cessation, and lifestyle modification for dry AMD, with immediate anti-VEGF therapy for any neovascular conversion 1, 2, 3. Light therapy remains investigational with insufficient evidence to support clinical use outside research protocols 4, 5, 6, 7, 8.